|
CA2841142C
(en)
|
2010-06-23 |
2020-12-15 |
Ryan D. Morin |
Biomarkers for non-hodgkin lymphomas and uses thereof
|
|
JO3363B1
(ar)
|
2011-04-13 |
2019-03-13 |
Epizyme Inc |
مركبات بنزين مستبدلة بأريل أو أريل غير متجانس
|
|
WO2013075084A1
(en)
|
2011-11-18 |
2013-05-23 |
Constellation Pharmaceuticals |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9085583B2
(en)
|
2012-02-10 |
2015-07-21 |
Constellation—Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
EP2836216B1
(en)
*
|
2012-04-13 |
2022-06-08 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
ES2617379T3
(es)
|
2012-04-13 |
2017-06-16 |
Epizyme, Inc. |
Forma de sal de un inhibidor de histona metiltransferasa EZH2 humana
|
|
JP6254169B2
(ja)
*
|
2012-09-28 |
2017-12-27 |
ファイザー・インク |
ベンズアミドおよびヘテロベンズアミド化合物
|
|
BR112015008480A2
(pt)
*
|
2012-10-15 |
2017-07-04 |
Epizyme Inc |
compostos de benzeno substituído
|
|
KR20190105669A
(ko)
|
2012-10-15 |
2019-09-17 |
에피자임, 인코포레이티드 |
암을 치료하는 방법
|
|
US9745305B2
(en)
|
2013-03-15 |
2017-08-29 |
Constellation Pharmaceuticals, Inc. |
Modulators of methyl modifying enzymes, compositions and uses thereof
|
|
US9969716B2
(en)
|
2013-08-15 |
2018-05-15 |
Constellation Pharmaceuticals, Inc. |
Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
|
|
PE20161273A1
(es)
|
2013-10-16 |
2016-12-18 |
Epizyme Inc |
Forma salina de hidrocloruro para la inhibicion de ezh2
|
|
WO2015058125A1
(en)
*
|
2013-10-18 |
2015-04-23 |
Epizyme, Inc. |
Method of treating cancer
|
|
MX373187B
(es)
|
2013-12-06 |
2020-04-13 |
Epizyme Inc |
Terapia de combinación para tratar cáncer.
|
|
US20160361309A1
(en)
*
|
2014-02-26 |
2016-12-15 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Methods of treating cancer patients responding to ezh2 inhibitor gsk126
|
|
EA038337B1
(ru)
*
|
2014-06-17 |
2021-08-11 |
Эпизим, Инк. |
Ингибиторы ezh2 для лечения лимфомы
|
|
CN106795561B
(zh)
|
2014-06-19 |
2021-04-16 |
纪念斯隆-凯特琳癌症中心 |
用于对ezh2抑制剂的应答的生物标志物
|
|
CN106794177A
(zh)
*
|
2014-10-16 |
2017-05-31 |
Epizyme股份有限公司 |
治疗癌症的方法
|
|
CA2964629A1
(en)
|
2014-11-06 |
2016-05-12 |
Dana-Farber Cancer Institute, Inc. |
Ezh2 inhibitors and uses thereof
|
|
KR102964530B1
(ko)
*
|
2014-11-17 |
2026-05-13 |
에피자임, 인코포레이티드 |
암을 치료하기 위한 방법
|
|
MX375970B
(es)
|
2014-12-23 |
2025-03-06 |
Novartis Ag |
Compuestos de triazolopirimidina y usos de los mismos.
|
|
WO2016172332A1
(en)
*
|
2015-04-22 |
2016-10-27 |
The University Of North Carolina At Chapel Hill |
A novel compound for the treatment of ewing sarcoma and high-throughput assays for identifying small molecules that modulate aberrant chromatin accessibility
|
|
EA201890009A1
(ru)
|
2015-06-10 |
2018-07-31 |
Эпизайм, Инк. |
Ингибиторы ezh2 для лечения лимфомы
|
|
WO2017035234A1
(en)
|
2015-08-24 |
2017-03-02 |
Epizyme, Inc. |
Method for treating cancer
|
|
TW201718598A
(zh)
|
2015-08-27 |
2017-06-01 |
美國禮來大藥廠 |
Ezh2抑制劑
|
|
WO2017040190A1
(en)
|
2015-08-28 |
2017-03-09 |
Constellation Pharmaceuticals, Inc. |
Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide
|
|
US20180296563A1
(en)
*
|
2015-09-25 |
2018-10-18 |
Epizyme, Inc. |
Method of treating malignant rhabdoid tumor of the ovary (mrto)/small cell cancer of the ovary of the hypercalcemic type(sccoht) with an ezh2 inhibitor
|
|
EP3371601A1
(en)
|
2015-11-05 |
2018-09-12 |
Epizyme Inc |
Flow cytometry for monitoring histone h3 methylation status
|
|
WO2017184999A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Dana-Farber Cancer Institute, Inc. |
Ezh2 inhibitors and uses thereof
|
|
US10933068B2
(en)
*
|
2016-05-26 |
2021-03-02 |
Sonic Master Limited |
Modulators of DUX4 for regulation of muscle function
|
|
US11786533B2
(en)
|
2016-06-01 |
2023-10-17 |
Epizyme, Inc. |
Use of EZH2 inhibitors for treating cancer
|
|
US11147819B2
(en)
|
2016-06-17 |
2021-10-19 |
Epizyme, Inc. |
EZH2 inhibitors for treating cancer
|
|
US10689378B2
(en)
|
2016-06-20 |
2020-06-23 |
Novartis Ag |
Triazolopyridine compounds and uses thereof
|
|
JP2019524872A
(ja)
|
2016-06-20 |
2019-09-05 |
ノバルティス アーゲー |
癌の治療に有用なイミダゾピリミジン化合物
|
|
JP7042812B2
(ja)
|
2016-06-20 |
2022-03-28 |
ノバルティス アーゲー |
トリアゾロピリミジン化合物の結晶形態
|
|
WO2018075598A1
(en)
|
2016-10-19 |
2018-04-26 |
Constellation Pharmaceuticals, Inc. |
Synthesis of inhibitors of ezh2
|
|
CA3044691A1
(en)
|
2016-10-26 |
2018-05-03 |
Genea Biocells USA (Holdings), Inc. |
Improved generation of muscle lineage cells and therapeutic uses thereof
|
|
EP3441388A1
(en)
*
|
2016-11-11 |
2019-02-13 |
Shanghai Haiyan Pharmaceutical Technology Co., Ltd. |
4,5,6-tri-substituted indazoles derivatives, preparation thereof, and use thereof in medicines
|
|
CN106963765B
(zh)
*
|
2017-03-28 |
2020-04-07 |
上海交通大学医学院附属第九人民医院 |
Ezh2抑制剂化合物在制备治疗眼部黑色素瘤的药物中的应用
|
|
WO2018183885A1
(en)
|
2017-03-31 |
2018-10-04 |
Epizyme, Inc. |
Combination therapy for treating cancer
|
|
AU2018275123A1
(en)
|
2017-06-02 |
2020-01-30 |
Epizyme, Inc. |
Use of EZH2 inhibitors for treating cancer
|
|
ES2977589T3
(es)
|
2017-08-18 |
2024-08-27 |
Cothera Bioscience Inc |
Forma polimórfica de TG02
|
|
JP7399079B2
(ja)
|
2017-09-05 |
2023-12-15 |
エピザイム,インコーポレイティド |
癌を処置するための併用療法
|
|
WO2019204998A1
(zh)
*
|
2018-04-25 |
2019-10-31 |
北京肿瘤医院 |
Ezh2抑制剂在治疗粘膜型黑色素瘤中的应用
|
|
EP3801497B1
(en)
*
|
2018-06-03 |
2023-03-22 |
Wen-Pin Chen |
Method for treating non-compaction cardiomyopathy
|
|
JP7411256B2
(ja)
*
|
2018-07-27 |
2024-01-11 |
エボポイント、バイオサイエンシズ、カンパニー、リミテッド |
多置換ベンゼン環化合物、製造方法及びその用途
|
|
ES3034869T3
(en)
|
2019-04-22 |
2025-08-25 |
Univ Pittsburgh Commonwealth Sys Higher Education |
Tg02 for use in treating gliomas in pediatric subjects
|
|
CN110960525A
(zh)
*
|
2019-11-26 |
2020-04-07 |
济南大学 |
新型eed-ezh2相互作用抑制剂的确定和评价
|
|
CN113024516B
(zh)
*
|
2021-03-29 |
2022-05-17 |
中国药科大学 |
双靶点parp/ezh2抑制剂、制备方法及用途
|
|
EP4392034A1
(en)
|
2021-08-25 |
2024-07-03 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Use of ezh2 inhibitors for the treatment of aortic valve stenosis
|
|
KR20260019479A
(ko)
|
2023-05-04 |
2026-02-10 |
레볼루션 메디슨즈, 인크. |
Ras 관련 질환 또는 장애를 위한 병용 요법
|
|
CN121889155A
(zh)
|
2023-08-07 |
2026-04-17 |
锐新医药公司 |
用于治疗ras蛋白相关疾病或病症的rmc-6291
|
|
AU2024360465A1
(en)
|
2023-10-12 |
2026-04-09 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
|
WO2025171296A1
(en)
|
2024-02-09 |
2025-08-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2025240847A1
(en)
|
2024-05-17 |
2025-11-20 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20250375445A1
(en)
|
2024-06-07 |
2025-12-11 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2025265060A1
(en)
|
2024-06-21 |
2025-12-26 |
Revolution Medicines, Inc. |
Therapeutic compositions and methods for managing treatment-related effects
|
|
WO2026006747A1
(en)
|
2024-06-28 |
2026-01-02 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026015796A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015801A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015790A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Methods of treating a ras related disease or disorder
|
|
WO2026015825A1
(en)
|
2024-07-12 |
2026-01-15 |
Revolution Medicines, Inc. |
Use of ras inhibitor for treating pancreatic cancer
|
|
WO2026050446A1
(en)
|
2024-08-29 |
2026-03-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
CN119143880A
(zh)
*
|
2024-09-20 |
2024-12-17 |
上海交通大学医学院附属第九人民医院 |
抗ezh2蛋白抗体及其应用
|
|
WO2026072904A2
(en)
|
2024-09-26 |
2026-04-02 |
Revolution Medicines, Inc. |
Compositions and methods for treating lung cancer
|
|
WO2026090116A2
(en)
|
2024-10-21 |
2026-04-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
US20260108528A1
(en)
|
2024-10-22 |
2026-04-23 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
|
WO2026090245A1
(en)
|
2024-10-22 |
2026-04-30 |
Revolution Medicines, Inc. |
Use of ras inhibitors for treating cancer
|
|
WO2026106912A1
(en)
|
2024-11-12 |
2026-05-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026112260A1
(en)
|
2024-11-21 |
2026-05-28 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026122764A2
(en)
|
2024-12-06 |
2026-06-11 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026128688A2
(en)
|
2024-12-13 |
2026-06-18 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
WO2026161839A1
(en)
|
2025-01-27 |
2026-07-30 |
Revolution Medicines, Inc. |
Ras inhibitors
|